TiGenix Living Medicines is a Belgium-based company that specializes in providing commercial cell therapy products and clinical trials. It operates under the principle that the health care industry’s next revolution will be in cell therapy. In 2011, TiGenix merged with the Spain-based cell therapy and biotechnology company, Cellerix. The merger combined the two companies’ executive management positions and oversight boards, as well as their workforce, and resulted in a new TiGenix, the name by which the combined company is referred.

Since the merger, the company gained additional operations based in Spain and the Netherlands. TiGenix’s managing director and chief executive officer is Eduardo Bravo, an executive with more than 20 years in the pharmaceutical industry. TiGenix’s chief technical officer is Wilfried Dalemans, who holds a PhD ...